Evidence map›Paper›PMID 42732353›Full record

ArticleCureus2026

Dose Conversion Ratio Between Roxadustat and Daprodustat in Patients With Non-dialysis Chronic Kidney Disease.

Keiji Hirai, Junki Morino, Katsunori Yanai, Yuko Mutsuyoshi, Taisuke Kitano, Haruhisa Miyazawa, Kiyonori Ito, Takahiro Masuda, Susumu Ookawara, Yoshiyuki Morishita

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Keiji HiraiDivision of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, JPN.
Junki MorinoDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, JPN.
Katsunori YanaiDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, JPN.
Yuko MutsuyoshiDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, JPN.
Taisuke KitanoDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, JPN.
Haruhisa MiyazawaDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, JPN.
Kiyonori ItoDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, JPN.
Takahiro MasudaDivision of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, JPN.
Susumu OokawaraDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, JPN.
Yoshiyuki MorishitaDivision of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to determine the dose conversion ratio between roxadustat and daprodustat in non-dialysis chronic kidney disease (CKD) patients by switching from roxadustat to daprodustat.

methodsChanges in hemoglobin, serum ferritin, transferrin saturation, and the doses of roxadustat and daprodustat were retrospectively analyzed in 15 patients (mean hemoglobin concentration: 11.2 ± 0.9 g/dL; mean estimated glomerular filtration rate: 14.3 ± 9.4 mL/min/1.73 m

resultsHemoglobin, serum ferritin concentrations, and transferrin saturation did not change after switching from roxadustat to daprodustat. The dose of roxadustat before switching was 51 ± 18 mg/administration, whereas the dose of daprodust at 12 months after switching was 5.2 ± 2.8 mg/administration. Accordingly, the dose conversion ratio between roxadustat and daprodustat was approximately 10:1 (51 ÷ 5.2 ≈ 10).

conclusionOur study results suggest that the dose conversion ratio between roxadustat and daprodustat is approximately 10:1 in non-dialysis CKD patients.

Indexed as

anemiachronic kidney diseasedaprodustathif-ph inhibitorroxadustat

Identifiers

PMID42732353
PMCPMC13570561

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.